References
- Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999; 35: 1688–92.
- Lissoni P, Bolis S, Brivio F, Fumagalli L. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Res 2000; 20: 2103–5.
- Lissoni P, Barni S, Tancini G, Brivio F, Tisi E, Zubelewicz B, et al. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin. J Biol Regul Homeost Agents 1994; 8: 126–9.
- Lissoni P. Paolorossi F, Tancini G, Barni S, Ardizzoia A, Brivio F, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32A: 1340–3.
- Sateia MJ, Silberfarb PM. Sleep. In: Doyle D, Hanks GW, MacDonald N, editors. Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press, 1998: 751–67.
- Engstrom CA, Strohl RA, Rose L, Lewandowski L, Stefanek ME. Sleep alterations in cancer patients. Cancer Nurs 1999; 22: 143–8.
- Beszterczey A, Lipowski ZJ. Insomnia in cancer patients. (Letter). Can Med Assoc J 1977; 116: 355.
- Skene DJ, Lockley SW, Arendt J. Use of melatonin in the treatment of phase shift and sleep disorders. Adv Expl Med Biol 1999; 467: 79–84.
- Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 2000; 343: 1070–7.
- Nagtegaal JE, Laurant MW, Kerkhof GA, Smits MG, van der Meer YG, Coenen AM. Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. J Psychosom Res 2000; 48: 45–50.